tailieunhanh - Báo cáo y học: " Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa | Wang et al. Virology Journal 2011 8 28 http content 8 1 28 J VIROLOGY JOURNAL RESEARCH Open Access Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa Shaoyang Wang Dedong Huang Shunlai Sun Weimin Ma Qin Zhen Abstract In order to examine whether variation in interleukin-10 promoter polymorphism would predict the likelihood of sustain response of chronic hepatitis B to treatment with interferon alfa IFN-a the inheritance of 3 biallelic polymorphisms in the IL-10 gene promoter in patients with 52 chronic hepatitis B were determined by polymerase chain reaction PCR -bared techniques restriction enzyme digestion or direct sequencing. The relationship to the outcome of antiviral therapy for chronic HBV infection was studied in 24 patients who had a virologically sustained response SR and in 28 non-responder NR to interferon alfa-2b and several IL-10 variants were more frequent among SR compared with NR. Carriage of the -592A allele -592A A genotype and -1082 -1819 -592 ATA haplotype was associated with SR. Our findings indicate that heterogeneity in the promoter region of the IL-10 gene has a role in determining the initial response of chronic hepatitis B to IFN-a therapy. Introduction Hepatitis B is a worldwide disease and remains a significant etiology of chronic hepatitis cirrhosis and hepatocellular carcinoma especially in several areas of Asia and Africa 1 . It is estimated to affect over 350 million people worldwide with a mortality of over million deaths per year because of acute or chronic hepatitis B infection 2 3 . For active hepatitis B patients with detectable hepatitis B virus e antigen HBeAg or hepatitis B virus HBV DNA and elevated alanine aminotransferase ALT serum levels treatment is often recommended. Six-month course of interferon alfa IFN-a therapy has been shown to induce a long-term sustained remission in 25 to 40 of chronic hepatitis B patients 1 4 5 . However the question